These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 957360)

  • 1. Three and one-half years' experience with a lower-dose combination oral contraceptive.
    Woutersz TB
    J Reprod Med; 1976 Jun; 16(6):338-44. PubMed ID: 957360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new ultra-low-dose combination oral contraceptive.
    Woutersz TB
    J Reprod Med; 1983 Jan; 28(1 Suppl):81-4. PubMed ID: 6403705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A low-dose combination oral contraceptive. Experience with 1,700 women treated for 22,489 cycles.
    Woutersz TB
    J Reprod Med; 1981 Dec; 26(12):615-20. PubMed ID: 7033528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profile of a new low dose combination estrogen and progestogen oral contraceptive: a review of nine clinical studies.
    Woutersz TB
    J Reprod Med; 1975 Sep; 15(3):87-92. PubMed ID: 1214254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with a new low dose oral contraceptive: norgestimate & ethinyl estradiol.
    Rubio-Lotvin B; Gonzales-Ansorena R
    Acta Eur Fertil; 1978 Mar; 9(1):1-6. PubMed ID: 696184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with a low-dose contraceptive agent. European studies.
    Haspels AA
    J Reprod Med; 1983 Jan; 28(1 Suppl):71-6. PubMed ID: 6403703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral contraceptives according to the normophasic principle.
    Borglin NE; Klottrup P
    Arzneimittelforschung; 1978; 28(12):2354-7. PubMed ID: 582954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J
    Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contraception with levonorgestrel, 0.15 mg, and ethinyl estradiol, 0.03 mg. Clinical studies in Latin America.
    Moggia AV
    J Reprod Med; 1983 Jan; 28(1 Suppl):77-80. PubMed ID: 6403704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of the ratio of levonorgestrel, 0.15 mg, to ethinyl estradiol, 0.03 mg.
    Christie T
    J Reprod Med; 1983 Jan; 28(1 Suppl):63-5. PubMed ID: 6403701
    [No Abstract]   [Full Text] [Related]  

  • 11. Oral contraception, 1986. Focus on Triphasil.
    Ellsworth H
    J Reprod Med; 1986 Jun; 31(6 Suppl):559-64. PubMed ID: 3522896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical use of combined contraceptive preparations of Hungarian manufacture].
    Farkas M
    Akush Ginekol (Mosk); 1983 Nov; (11):11-4. PubMed ID: 6364870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The efficacy of gestoden (delta 15-d-norgestrel) as ovulation inhibitor (author's transl)].
    Schneider WH; Schmid R; Spona J
    Wien Klin Wochenschr; 1981 Oct; 93(19):601-4. PubMed ID: 6798765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of Ovidon, Rigevidon and Postinor for contraception].
    Kulakov VI; Barinov AM; Prilepskaia VN
    Akush Ginekol (Mosk); 1983 Nov; (11):22-4. PubMed ID: 6666791
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical experiences with femovan (Gynera)].
    Brill K; Düsterberg B; Albring M
    Ther Umsch; 1990 Dec; 47(12):958-65. PubMed ID: 2096480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary results from a swedish multicenter trial of a new low dose combined oral contraceptive.
    Ingemanson CA; Jägerhorn M; Zizala J; Nilsson B; Zador G
    Acta Obstet Gynecol Scand Suppl; 1976; 54():71-5. PubMed ID: 788449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four years overall experience with a new low estrogen -- low progestogen oral contraceptive.
    Brat T
    Acta Obstet Gynecol Scand Suppl; 1976; 54():67-70. PubMed ID: 788448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year, multicenter study of a triphasic, low-dose, combination oral contraceptive.
    Woutersz TB; Korba VD
    Int J Fertil; 1988; 33(6):406-10. PubMed ID: 2906915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.